Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice

Blood

Volumn 124, Issue 18, 2014, Pages 2847-2857

  Hsieh, Wan Chen ^a,b   Chuang, Ya Ting ^c   Chiang, I Hsuan ^b,d   Hsu, Shu Ching ^e   Miaw, Shi Chuen ^d   Lai, Ming Zong ^a,b,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CURDLAN; CYTOKINE; DECTIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 10; RAC1 PROTEIN; RESOLVIN D1; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; BCL10 PROTEIN, MOUSE; BETA GLUCAN; BIRC4 PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; LECTIN; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIGEN RECEPTOR; LYSINE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; PAM(3)CSK(4) PEPTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN BINDING; RESIQUIMOD; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INNATE IMMUNITY; KNOCKOUT MOUSE; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN PROTEIN INTERACTION; UBIQUITINATION; UPREGULATION; X LINKED LYMPHOPROLIFERATIVE SYNDROME TYPE 2; AGONISTS; ANIMAL; DEFICIENCY; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; X CHROMOSOME LINKED DISORDER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BETA-GLUCANS; CANDIDA ALBICANS; CANDIDIASIS; GENETIC DISEASES, X-LINKED; HUMANS; IMIDAZOLES; IMMUNITY, INNATE; INHIBITOR OF APOPTOSIS PROTEINS; LECTINS, C-TYPE; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; LYMPHOPROLIFERATIVE DISORDERS; LYSINE; LYSOPHOSPHOLIPIDS; MACROPHAGES; MICE; NF-KAPPA B; PHAGOCYTOSIS; POLY I-C; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION;

EID: 84908599594     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-564609     Document Type: Article

References (55)

1. Picard C, Puel A, Bonnet M., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003; 299(5615):2076-2079.
2. Zhang SY, Jouanguy E, Ugolini S., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007; 317(5844): 1522-1527.
3. Netea MG, van de Veerdonk FL, van der Meer JW. Primary immunodeficiencies of pattern recognition receptors. J Intern Med. 2012; 272(6): 517-527.
4. Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol. 2013; 13(9):635-648.
5. Marks DJ. Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity? Curr Opin Gastroenterol. 2011; 27(4): 328-334.
6. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature. 2011; 469(7330):323-335.
7. Vinh DC, Behr MA. Crohn's as an immune deficiency: from apparent paradox to evolving paradigm. Expert Rev Clin Immunol. 2013; 9(1): 17-30.
8. Rigaud S, Fondanèche MC, Lambert N., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006; 444(7115):110-114.
9. Filipovich AH, Zhang K, Snow A.L., Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010; 116(18): 3398-3408.
10. Pachlopnik Schmid J, Canioni D, Moshous D., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011; 117(5):1522-1529.
11. Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem. 2006; 281(6): 3254-3260.
12. Galbán S, Duckett CS. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ. 2010; 17(1): 54-60.
13. Harlin H, Reffey SB, Duckett C.S., Lindsten T., Thompson CB. Characterization of XIAP-deficient mice. Mol Cell Biol. 2001; 21(10):3604-3608.
14. Olayioye MA, Kaufmann H, Pakusch M., Vaux DL, Lindeman GJ, Visvader JE. XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland. Cell Death Differ. 2005; 12(1): 87-90.
15. Rumble JM, Oetjen KA, Stein P.L., Schwartzberg PL, Moore BB, Duckett CS. Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP). Cell Immunol. 2009; 259(1):82-89.
16. Bauler LD, Duckett CS, O'Riordan MX. XIAP regulates cytosol-specific innate immunity to Listeria infection. PLoS Pathog. 2008; 4(8): e1000142.
17. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder B.R., Lipp J., de Martin R. Activation of NF-κB by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem. 2000; 275(29):22064-22068.
18. Levkau B, Garton KJ, Ferri N, et al. xIAP induces cell-cycle arrest and activates nuclear factor-kappaB: new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res. 2001; 88(3): 282-290.
19. Lewis J, Burstein E, Reffey S.B., Bratton SB, Roberts AB, Duckett CS. Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. J Biol Chem. 2004; 279(10):9023-9029.
20. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007; 131(4):682-693.
21. Varfolomeev E, Goncharov T, Fedorova A.V., et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008; 283(36):24295-24299.
22. Damgaard RB, Nachbur U, Yabal M., et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012; 46(6):746-758.
23. Gross O, Gewies A, Finger K., et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature. 2006; 442(7103): 651-656.
24. Rawlings DJ, Sommer K, Moreno-García ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol. 2006; 6(11): 799-812.
25. Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol. 2012; 30: 491-529.
26. Hardison SE, Brown GD. C-type lectin receptors orchestrate antifungal immunity. Nat Immunol. 2012; 13(9):817-822.
27. Strasser D, Neumann K, Bergmann H., et al. Syk kinase-coupled C-type lectin receptors engage protein kinase C-ω to elicit Card9 adaptor-mediated innate immunity. Immunity. 2012; 36(1): 32-42.
28. Leibund Gut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007; 8(6):630-638.
29. Liu WH, Hsiao HW, Tsou W.I., Lai MZ. Notch inhibits apoptosis by direct interference with XIAP ubiquitination and degradation. EMBO J. 2007; 26(6):1660-1669.
30. Serhan CN, Hong S, Gronert K., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002; 196(8):1025-1037.
31. Sun YP, Oh SF, Uddin J, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007; 282(13):9323-9334.
32. Rogerio AP, Haworth O, Croze R., et al. Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J Immunol. 2012; 189(4):1983-1991.
33. Hu S, Alcivar A, Qu L., Tang J, Yang X. CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation. Cell Cycle. 2006; 5(13): 1438-1442.
34. Wu CJ, Ashwell JD. NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc Natl Acad Sci USA. 2008; 105(8):3023-3028.
35. Zhou H, Wertz I, O'Rourke K, et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature. 2004; 427(6970): 167-171.
36. Sun L, Deng L, Ea C.K., Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell. 2004; 14(3):289-301.
37. Wertz IE, Dixit VM. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol. 2010; 2(3):a003350.
38. Thome M, Charton JE, Pelzer C, Hailfinger S. Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol. 2010; 2(9):a003004.
39. Grabiner BC, Blonska M, Lin P.C., et al. CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-κB activation. Genes Dev. 2007; 21(8):984-996.
40. Wang D, You Y, Lin P.C., et al. Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors. Proc Natl Acad Sci USA. 2007; 104(1):145-150.
41. Wegener E, Krappmann D. CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB. Sci STKE. 2007; 2007(384): pe21.
42. Jiang T, Grabiner B, Zhu Y., et al. CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. Cancer Res. 2011; 71(6): 2183-2192.
43. Jiang C, Lin X. Regulation of NF-κB by the CARD proteins. Immunol Rev. 2012; 246(1):141-153.
44. Shambharkar PB, Blonska M, Pappu B.P., et al. Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways. EMBO J. 2007; 26(7):1794-1805.
45. Taylor PR, Tsoni SV, Willment J.A., et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007; 8(1):31-38.
46. Saijo S, Ikeda S, Yamabe K., et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity. 2010; 32(5):681-691.
47. Marion S, Mazzolini J, Herit F., et al. The NF-κB signaling protein Bcl10 regulates actin dynamics by controlling AP1 and OCRL-bearing vesicles. Dev Cell. 2012; 23(5):954-967.
48. Krishnamoorthy S, Recchiuti A, Chiang N., et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA. 2010; 107(4):1660-1665.
49. Hsiao HM, Sapinoro RE, Thatcher T.H., et al. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE. 2013; 8(3): e58258.
50. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009; 461(7268): 1287-1291.
51. Krishnamoorthy S, Recchiuti A, Chiang N., Fredman G, Serhan CN. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012; 180(5):2018-2027.
52. Liston A, Enders A, Siggs OM. Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol. 2008; 8(7):545-558.
53. Marsh RA, Rao K, Satwani P., et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013; 121(6):877-883.
54. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012; 18(4):509-519.
55. Brain O, Allan P, Simmons A. NOD2-mediated autophagy and Crohn disease. Autophagy. 2010; 6(3):412-414.